OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, ...

This is an observer-blinded, three-arms study in 376 patients in Chinese individuals aged from 18 to 55 years old who had previously received three doses COVID-19 vaccine. Immunogenicity in terms of ...

Please provide your email address to receive an email when new articles are posted on . A post hoc analysis of phase 3 trial data showed no association of immunogenicity with efficacy or safety for ...

Scientists working for Novartis have taken a step forward in better understanding how new classes of biological drugs might affect patients’ immune systems. Paul Wassmann, PhD senior principal ...

In a recent study published in Scientific Reports, researchers characterized the immunogenicity and safety of poxvirus-based Nipah vaccines that can be used in humans and species responsible for Nipah ...

Assessing immunogenicity is a cornerstone of modern drug development, especially for biologics and vaccines. Understanding how the immune system interacts with therapeutic agents is essential to ...

In a recent study posted to Preprints with The Lancet*, researchers evaluated the immunogenicity of Pfizer’s BNT162b2 and Moderna’s messenger ribonucleic acid (mRNA-1273) vaccines offered as the ...

Please provide your email address to receive an email when new articles are posted on . Although immune-based therapies have penetrated many medical specialties, including rheumatology, some experts ...

A total of 59 patients received UCPVax; 95% had three prior lines of systemic therapy. No dose-limiting toxicity was observed in 15 patients treated in phase Ib. The maximum tolerated dose was 1 mg.

One-year trial shows AVT05 golimumab biosimilar matches Simponi in rheumatoid arthritis, including switching, with comparable ...